MiMedx Group has signed a definitive merger agreement to acquire Sanara MedTech. Under the deal, MiMedx's merger subsidiary will combine with Sanara, and Sanara will continue as a wholly owned subsidiary. Sanara stockholders will get $33.00 in cash plus 0.4735 MiMedx shares (valued at about $2.00) for each share, and the boards of both companies unanimously approved the transaction. The deal is subject to Sanara stockholder approval and other customary conditions, and MiMedx will file an S-4 registration statement with the SEC.
View Full Filing (SEC EDGAR)